<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570908</url>
  </required_header>
  <id_info>
    <org_study_id>H-20924</org_study_id>
    <secondary_id>H 20924</secondary_id>
    <nct_id>NCT00570908</nct_id>
  </id_info>
  <brief_title>Brain Mets - Capecitabine Plus Sunitinib and WBRT</brief_title>
  <official_title>A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of concurrent whole brain
      radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in
      treating patients with CNS metastases from breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central nervous system (CNS) metastases is the most common type of brain malignancy, and
      breast cancer is the second most common type of malignancy to cause CNS metastases. Although
      the incidence of CNS metastases is less common than bone or visceral metastases, it is
      associated with poorer prognosis and is relatively unresponsive to systemic therapies. The
      incidence of CNS metastases in breast cancer has been estimated as 1-16% in clinical series,
      with higher rates (18-30%) in autopsy series. Recently a trend towards increasing CNS relapse
      has been noted, up to 25-34%. This may be partly explained by the increasing use of
      contrast-enhanced magnetic resonance imaging (MRI), heightened awareness by patient or
      clinicians, or an alteration in the natural history of breast cancer with improvements in
      systemic therapies, resulting in a prolongation of survival. Therefore, with improvements in
      treatments, metastases are better controlled, resulting in the CNS becoming a sanctuary for
      residual disease. The treatment of CNS metastases in breast cancer remains challenging.
      Surgical resection of tumor will prolong survival only in patients with a single lesion and
      with well controlled systemic disease. For patients with multiple lesions, whole brain
      radiotherapy (WBRT) remains the backbone in the management of CNS metastases. Recently the
      use of stereotactic radiosurgery alone or in combination with WBRT has been explored.
      Although better local control was achieved with the combination therapy, minimal overall
      survival benefit was seen. This may be secondary to the competing risk of death from systemic
      (extra-CNS) progression. The use of systemic agents including chemotherapy and hormonal
      therapy has been generally disappointing. This is often attributed to the impermeability of
      the blood-brain and blood-tumor barriers. Furthermore, P-glycoprotein (Pgp), a drug efflux
      pump encoded by the multidrug resistance gene, mdR1, is expressed in brain endothelial cells.
      Therefore, agents such as doxorubicin, cyclophosphamide, 5-fluorouracil, paclitaxel,
      docetaxel and vinorelbine, which are active against breast cancer, may either penetrate CNS
      poorly, or be transported out of the CNS environment. However, the blood brain barrier may be
      more leaky and permeable than previously thought in patients with CNS metastases, and these
      agents may achieve therapeutic concentrations in the CNS. As evidence for this, patients
      without prior exposure to agents such as cyclophosphamide, methotrexate, 5-fluorouracil,
      vincristine, and doxorubicin, can have significant objective responses in the CNS metastases.
      Today, most patients would have received these agents in the adjuvant setting, thus
      emphasizing the importance of both chemo-sensitivity together with CNS penetration, in the
      treatment of CNS metastases.

      This is a single arm, open label, phase II drug study. This study will be conducted at the
      Breast Care Center at Baylor College of Medicine and its affiliated hospital, and at Ben Taub
      General Hospital in Houston. Patients who were diagnosed with CNS metastases (brain +/-
      leptomeningeal disease) will be identified prospectively. All eligible patients will receive
      capecitabine concurrently with WBRT followed by combination capecitabine with sunitinib. WBRT
      will be administered at 30 Gy in 10 fractions together with capecitabine to be given on the
      first day of WBRT at 1000 mg/m2/day and continued daily for 14 days. After a 7 days rest
      period, capecitabine will be restarted at 2000mg/m2/day for 14 days followed by a 7 days rest
      period. This will be given together with sunitinib at 37.5 mg daily. This is the dosing
      determined by the phase I study with capecitabine and sunitinib. Dose reduction and/or
      treatment postponement will be done for significant toxicity. Capecitabine with sunitinib
      will be administered until disease progression in either CNS and/or non-CNS sites. Efficacy
      assessments will be performed on all subjects via imaging studies in the CNS and extra-CNS
      sites 8 weeks after starting study, then every 12 weekly. Neurological examination will be
      performed at baseline, 3 weeks after starting treatment, then every 6 weekly. Assessment of
      treatment toxicity will be performed at baseline, 3 weeks after starting treatment, then
      every 3 weekly using the NCI Common Toxicity grading system. Clinical and laboratory
      parameters will be assessed until disease progression or withdrawal from study (due to
      unacceptable toxicity or withdrawal of consent). Subjects with progression of CNS and / or
      extra-CNS disease will be considered progressors. Subjects withdrawn from treatment will be
      followed for survival until death.

      Primary endpoint: 1. To determine progression free survival. Progression will be defined by
      progression in either CNS or extra-CNS metastases. Secondary endpoint: 1. To assess the
      toxicities associated with the regimen 2. To determine the overall objective response in CNS
      disease 3. To determine the overall objective response in extra-CNS disease 4. To determine
      the overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual this study is being closed to accrual
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>Sutent</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>concurrently</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT</intervention_name>
    <description>Whole Brain Radiotherapy 30 Gy in 10 fractions</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Whole Brain Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must be age 18 or older. Histological or cytologically confirmed invasive breast
        cancer, with Stage IV disease.

        Evidence of radiographically measurable CNS metastases (greater than or equal to 10mm on
        T1-weighted gadolinium-enhanced MRI) within 2 weeks prior to starting treatment. Patients
        without known extra-CNS disease are eligible.

        Must have metastases in the brain. Patients with concurrent leptomeningeal carcinomatosis
        are eligible for the study. Local radiation to sites of meningeal involvement in the spine
        is allowed.

        No prior whole brain radiation. Patients who had previous stereotactic brain irradiation
        are eligible, provided they have new measurable brain lesions (which has not been radiated
        previously) and will receive WBRT at 30Gy over 10 fractions.

        May undergo surgical resection of CNS metastases if clinically indicated, but must have
        remaining measurable disease in the brain after surgery.

        No prior treatment with capecitabine in the adjuvant or metastatic settings. Patients may
        have completed 5-fluorouracil based treatment in the adjuvant setting or metastatic setting
        more than one year prior.

        Patients who had previous trastuzumab therapy will be eligible but treatment will be
        discontinued prior to enrollment.

        Cardiac ejection fraction within institutional range of normal as measure by echocardiogram
        or MUGA scans at baseline.

        Hematological adequacy Hepatic adequacy Renal adequacy Must have recovered from toxicity of
        prior chemotherapy with laboratory values as specified above. Concurrent treatment with
        bisphosphonates is permitted. Performance status of ECOG 0-1.

        Life expectancy of at least 12 weeks. At least 3 weeks since major surgical procedures.
        Able to swallow and retain oral medication.

        Exclusion Criteria:

        Pregnant or breast feeding. Known allergy to capecitabine or 5-fluorouracil. Known to have
        dihydropyrimidine dehydrogenase (DPD) deficiency.

        Patients who have leptomeningeal carcinomatosis as the only site of CNS metastases.

        Patients taking concomitant medications which are CYP3A4 inhibitors or inducers.

        Patients who will receive intrathecal chemotherapy for leptomeningeal disease. Patients
        with psychiatric or addictive disorders that would adversely effect compliance with oral
        medication.

        Life expectancy less than 3 months. Symptomatic lymphangitic spread to lung. Malabsorption
        syndrome, disease significantly affecting gastrointestinal function, or resection of the
        stomach or small bowel.

        History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or
        other contraindication or gadolinium contrast.

        Other known contraindication to MRI, such as a cardiac pacemaker, implanted cardiac
        defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel,

        1Vascular disease within 12 months prior to enrollment Uncontrolled infection History of
        other malignancy, except for curatively treated basal cell carcinoma or squamous cell
        carcinoma of the skin, or carcinoma in situ of the cervix. Subjects with other malignancies
        who have been disease-free for at least 5 years are eligible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mothaffar` Rimawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine, Breast Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lester and Sue Smith Breast Center at Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <keyword>breast cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5">5 patients progressed during the study treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>12 patients were enrolled and started treatment</population>
      <group_list>
        <group group_id="B1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="32" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
        <time_frame>2 years</time_frame>
        <population>5 patients progressed during the study treatment. 7 patients were off study treatment early due to AE or withdrawal but 6 of them were followed for the survival outcome, 1 was lost to follow up after 3.5 months observation (censored data).</population>
        <group_list>
          <group group_id="O1">
            <title>WBRT + Capecitabine + Sunitinib</title>
            <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival is defined as form initiation of WBRT with capecitabine to the time of first documented progression at any site (CNS or non-CNS site) or death due to any cause, where progression is defined stringently by progression in either CNS or extra-CNS metastases.</description>
          <population>5 patients progressed during the study treatment. 7 patients were off study treatment early due to AE or withdrawal but 6 of them were followed for the survival outcome, 1 was lost to follow up after 3.5 months observation (censored data).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>WBRT + Capecitabine + Sunitinib</title>
          <description>capecitabine concurrently with WBRT(Whole Brain Radiotherapy 30 Gy in 10 fractions) followed by combination capecitabine with sunitinib(Sutent)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac - CHF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diabetetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (SOB)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ANC low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gums - Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Low WBC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>TSH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision - Flashing Lights</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis - Oral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatifue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>E. Coli Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection - Middle Ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection - Sinus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphate</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bilirubin, Elevated</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Pedal Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema - Right Axillary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash - Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mothaffar Rimawi</name_or_title>
      <organization>Baylor Coolege of Medicine</organization>
      <phone>7137981811</phone>
      <email>rimawi@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

